Taylor MAL 92‐4.

Methods	Centralised computer generated randomisation, allocation concealed in sealed envelopes opened in sequence, open‐label, microscopists blinded Withdrawn: AM = 12/95 (13%), QNN = 7/88 (8%) No loss to follow‐up reported
Participants	183 Malawian children with cerebral malaria, unrousable coma (Blantyre score 2 or less) and asexual falciparum parasitaemia Excluded: additional diagnosis; QNN or AM in previous week
Interventions	AMim vs QNNiv: 1. AM 3.2 mg/kg, then 1.6 mg/kg daily 2. QNN 20 mg/kg then 10 mg/kg every 8 h (minimum 3 intravenous doses, per os when able to drink) Fansidar (500 mg S, 25 mg P) given at parasite clearance and full recovery
Outcomes	1. Mortality (survival the major criterion for efficacy) 2. Neurological sequelae at 96h 3. FCT 4. PCT (50, 90, 100%) 5. Time to recover full consciousness (Blantyre score 5, or 4 in patients with compromised vision due to malaria) 6. Time to sit, stand, walk, drink, eat 7. Recrudescence at 7 d, 14 d, 21 d and 28 d
Notes	Quality assessment: A, A, A Artemetheri for injection 80 mg/ml, Kunming Pharmaceuticals Paluther 8% solution Rhone‐Poulenc, manufactured by Kunming Pharmaceuticals